Get the Stockscreener App
3.84
3.52%
-0.14
After Hours:
3.83
-0.010
-0.26%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $3.84, with a volume of 15.86M.
It is down -3.52% in the last 24 hours and down -85.52% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
See More
Previous Close:
$3.98
Open:
$3.93
24h Volume:
15.86M
Relative Volume:
3.85
Market Cap:
$184.74M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.7534
EPS:
-2.19
Net Cash Flow:
$-82.44M
1W Performance:
-85.50%
1M Performance:
-85.52%
6M Performance:
-81.95%
1Y Performance:
-81.30%
1-Day Range:
$3.77
$4.00
1-Week Range:
$3.65
$4.85
52-Week Range:
$3.65
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
3.84 | 184.74M | 0 | -97.22M | -82.44M | -2.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
A Post-Mortem on Cassava Sciences - MSN
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA) - MSN
HC Wainwright Has Negative Outlook of SAVA FY2024 Earnings - MarketBeat
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - AccessWire
Cassava Sciences: Probably The End Of The Saga (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences Stock Craters After Alzheimer’s Disease Trial Flops: Retail’s Devastated - MSN
A Post-Mortem On Cassava Sciences - Barchart
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops - MSN
A Controversial Alzheimer’s Drug Has Gone Down in Flames - Gizmodo
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin (SAVA) - Seeking Alpha
Cassava Sciences Faces Reality After Simufilam’s Phase 3 Failure (NASDAQ:SAVA) - Seeking Alpha
Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study - Yahoo Finance
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown - The Deep Dive
What’s in Cassava stock post Alzheimer’s setback (SAVA:NASDAQ) - Seeking Alpha
Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit - Notebookcheck.net
Cassava Sciences (NASDAQ:SAVA) Downgraded to Neutral Rating by HC Wainwright - MarketBeat
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails - MSN
HC Wainwright & Co. Downgrades Cassava Sciences (SAVA) - MSN
Cassava Sciences stock plummets after Phase III Alzheimer’s fail - MSN
SAVA Stock Touches 52-Week Low at $3.95 Amid Market Volatility - Investing.com India
Trial of controversial Alzheimer’s drug halted after disappointing results - The Seattle Times
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results - The New York Times
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Controversial Alzheimer’s drug from Cassava Sciences fails clinical testing - Science
Cassava Sciences' stock on track for biggest-ever selloff after failed Alzheimer's trial - MarketWatch
Cassava Sciences plummets over 80% on Alzheimer's trial fail - Yahoo Finance
Cassava crashes as Alzheimer’s dream dies - The Pharma Letter
Morning Brew: Cassava Sciences Plummets on Alzheimer's Trial Results - GuruFocus.com
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops - Fast Company
SAVACassava Sciences, Inc. Latest Stock News & Market Updates - StockTitan
Cassava shares sink on plans to stop Alzheimer's drug studies - Reuters
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update - Benzinga
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III - BioSpace
Cassava Sciences Alzheimer’s Drug Fails, Stocks Plunge - NewsX
Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial - Being Patient
Cassava Sciences' Controversial Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Halts Late-Stage Studies - Benzinga
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies - Benzinga
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study - Investopedia
Cassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study; Shares Dive -- Update - MarketWatch
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails - MarketWatch
Cassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study - MarketWatch
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints - GlobeNewswire
Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results - Inkl
Cassava Sciences to Hold Corporate Update on November 25th - Yahoo Finance
Cassava Sciences to Host Key Corporate Update on Alzheimer's Drug Development | SAVA Stock News - StockTitan
Cassava Sciences (NASDAQ:SAVA) Shares Gap DownTime to Sell? - MarketBeat
January 2025 Options Now Available For Cassava Sciences (SAVA) - Nasdaq
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? - MSN
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):